Ensidipine combined with venetoclax is a new combination therapy with high remission rate in the treatment of AML

In the field of leukemia treatment, ensidipine and venetoclax, two drugs with different mechanisms of action, have recently been jointly used to treat relapsed or refractory acute myeloid leukemia (AML) carryingIDH2 mutations, and have shown impressive efficacy.

The latest announced results of the phase 1b/2 ENAVEN-AML study show that the overall response rate (ORR) of combined use of ensidipine and venetoclax is as high as 70% for AML patients with IDH2 mutations, and the complete response rate (CR) is as high as 57%. This data provides new hope for patients who have not responded well to traditional treatments.

Ensidipine, as a small molecule inhibitor targetingIDH2 mutations, inhibits the proliferation of leukemia cells by reducing the activity of mutated IDH2 enzymes. As a bcl-2 inhibitor, venetoclax was originally mainly used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), but recent studies have found that it also shows significant therapeutic effects on AML when used in combination with ensidipine.

Although the combination of ensidipine and venetoclax has achieved significant efficacy in clinical trials, patients should still use caution when using it. Since drug interactions may affect drug efficacy and even increase the risk of adverse reactions, patients should undergo a comprehensive physical examination and receive treatment under the guidance of a doctor before using these two drugs.

In addition, each patient's physical condition and condition are unique, so doctors will take the patient's specific circumstances into consideration when formulating a treatment plan. If doctors believe that the combination of ensidipine and venetoclax would be beneficial to a patient, they will adjust the dosage and use of the drugs under close monitoring to ensure the safety and effectiveness of the treatment.

In summary, ensidipine combined with venetoclax provides a new and highly effective treatment option forAML patients with IDH2 mutations. However, when using these two drugs, patients should pay close attention to their own reactions and side effects of the drugs, and promptly report any discomfort or abnormalities to their doctors so that the treatment plan can be adjusted in a timely manner.